Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 5Venous Thromboembolism 3Venous Thrombosis 2Lung Neoplasms 2Thromboembolism 1Pulmonary Embolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Irinotecan 10Fluorouracil 10Leucovorin 9Bevacizumab 9Gemcitabine 8Paclitaxel 7Cisplatin 7Capecitabine 7Oxaliplatin 6130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 4Sorafenib 4Drug Therapy 4Cetuximab 4pembrolizumab 3apatinib 3Radiotherapy 3Ocoxin 3Imatinib Mesylate 3Folfox protocol 3Everolimus 3tislelizumab 2spartalizumab 2palbociclib 2entinostat 2encorafenib 2camrelizumab 2anlotinib 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Neoplasms × Nadroparin × Clear all
NCT00827554 2016-04-01

The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma

Eastern Hepatobiliary Surgery Hospital

Phase 2/3 Completed
100 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡